Market Research Logo

Neurological Biomarkers Market: Product Diversification Remains Key Strategy for Key Manufactures: Global Industry Analysis (2012 - 2016) and Forecast (2017 - 2025)

Neurological Biomarkers Market: Product Diversification Remains Key Strategy for Key Manufactures: Global Industry Analysis (2012 - 2016) and Forecast (2017 - 2025)

Genomics emerges as the trending biomarker type, and is expected to witness impressive growth

Neurology disorders are affecting major percentage of the global population and it is considered a major cause of disability around the globe. The prevalence of neurological disorders is growing at a very high pace, in which biomarkers are expected play a vital role in better understanding of the disease and development of personalized medicine specific to the patient. There are different types of biomarkers in the market, such as Genomics Biomarker, Proteomics Biomarker, Metabolomics Biomarkers, Imaging Biomarkers, Others. Among these, geonomics biomarker is expected to hold a higher market value reach over US$ 2,700 Mn by the end of 2025.

With the advancements taking place in the healthcare industry and expansion of neurological biomarkers market, new trends are being introduced in the market. A latest trend introduces genomics to the biomarkers market. The process is considered to be an efficient process of examining a disease at the genetic level. It can play major role in the drug development and personalized medicine too. Imaging biomarkers has also come up as one attractive biomarker type, which is expected to witness growth at a high rate in the years coming ahead. Metabolomics biomarkers is also one of these attractive category in the market which is expected to be a lucrative segment in the coming years.

Neurological biomarkers market stands strong in terms of business, as the market demands personalized medicines

Early diagnosis of neurological diseases plays a crucial role in successful management of the disease. Neurological system has limited accessibility and thus, makes diagnosis of the disease a difficult process. Moreover, presently available diagnostic procedures lack sensitivity and specificity for evaluation of disease progression and prognosis. Neurological disorders are diagnosed with cognitive testing, clinical history, structural MRI and neurological examination. However, there are few circumstances wherein identification of specific biomarker is required to understand the diagnosis and treatment of the disease. Biomarker is considered as an indicator in evaluation and measurement of a pathological and physiological process or indicator for pharmacological response to a treatment. Biomarkers are common reference point for diagnosis of disease and play a major role in the development of personalized medicine. There has been significant progress in understanding of onset and development of neurological diseases at the epigenomic and genomic levels. It leads to rapid development of biomarkers in diagnosis of disease with main emphasis in personalized medicine. The growth is expected to take place rapidly, with the requirements of personalized medicines in the coming years.

The market is expected to be stay active also with the increase in research initiatives taking place. There is a huge demand for identifying and validating biomarkers from a large number of population and conducting the research process with the help of this method. It is anticipated to be major factor marking the growth of neurological biomarkers market.

Heterogeneity of Disease turns out to be a stout hindrance in the growth of neurological biomarkers market

In case of heterogeneity, the same disease phenotype is produced with multiple interrelated processes and it increases the difficulty of discovery of biomarkers in degenerative diseases. Such cases can be misleading and increases the complications of the detection and analysis process. It leads to confusion between abnormal and normal health conditions. The clinical symptoms of one disease may be identified by number of heterogeneous Omics variations. Such cases can tone down the expectations of people from neurological biomarkers process and also hamper the growth of its market globally.


1. Executive Summary
A gist of the report, highlighting the key takeaways
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
A definition of Neurological Biomarkers and related market taxonomy
2.1. Market Definition
2.2. Market Taxonomy
2.3. Neurological Biomarkers Market Overview
2.4. Company and Chief Analyst Credentials
3. Market View Point
Tracking the market scenario, with key inferences drawn from historical data, current trends, and future prospects
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Technology Evolution and List of Neurological Biomarkers
4.2. List of Growth Hacking Manufacturers
5. Industry Structure
5.1. Marketing and Distribution Strategies
5.2. Market Size by Tiers
6. Macroeconomic Assumptions
7. Global Economic Outlook
7.1. Gross Domestic Product by Region & Country, 2006 – 2021
7.2. Disease Outlook
8. North America Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Market forecast and analysis in the U.S. and Canada
8.1. Introduction
8.2. Key Regulations
8.3. Regional Market Dynamics
8.3.1. Drivers
8.3.2. Restraints
8.3.3. Trends
8.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
8.4.1. U.S.
8.4.2. Canada
8.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
8.5.1. U.S.
8.5.2. Canada
8.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
8.6.1. Genomics Biomarker
8.6.2. Proteomic Biomarker
8.6.3. Metabolomics Biomarker
8.6.4. Imaging biomarkers
8.6.5. Others
8.7. Market Size (US$ Mn) Forecast By Type, 2017–2025
8.7.1. Genomics Biomarker
8.7.2. Proteomic Biomarker
8.7.3. Metabolomics Biomarker
8.7.4. Imaging biomarkers
8.7.5. Others
8.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
8.8.1. Alzheimer’s disease
8.8.2. Parkinson’s disease
8.8.3. Huntington’s disease
8.8.4. Schizophrenia
8.8.5. Depression
8.8.6. Multiple Sclerosis
8.8.7. Spinal Muscular Atrophy (SMA)
8.9. Market Size (US$ Mn) Forecast By Application, 2017-2025
8.9.1. Alzheimer’s disease
8.9.2. Parkinson’s disease
8.9.3. Huntington’s disease
8.9.4. Schizophrenia
8.9.5. Depression
8.9.6. Multiple Sclerosis
8.9.7. Spinal Muscular Atrophy (SMA)
8.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
8.10.1. Research Institutes and Diagnostic Centers
8.10.2. Hospitals
8.11. Market Size (US$ Mn) Forecast By End User, 2017-2025
8.11.1. Research Institutes and Diagnostic Centers
8.11.2. Hospitals
8.12. Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Type
8.12.3. By Application
8.12.4. By End User
8.13. Key Representative Market Participants
8.14. Key Participants Market Presence (Intensity Map)
9. Latin America Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Market forecast and analysis in Brazil, Mexico, Argentina and Rest of Latin America
9.1. Introduction
9.2. Key Regulations
9.3. Regional Market Dynamics
9.3.1. Drivers
9.3.2. Restraints
9.3.3. Trends
9.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Argentina
9.4.4. Rest of Latin America
9.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Argentina
9.5.4. Rest of Latin America
9.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
9.6.1. Genomics Biomarker
9.6.2. Proteomic Biomarker
9.6.3. Metabolomics Biomarker
9.6.4. Imaging biomarkers
9.6.5. Others
9.7. Market Size (US$ Mn) Forecast By Type, 2017–2025
9.7.1. Genomics Biomarker
9.7.2. Proteomic Biomarker
9.7.3. Metabolomics Biomarker
9.7.4. Imaging biomarkers
9.7.5. Others
9.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
9.8.1. Alzheimer’s disease
9.8.2. Parkinson’s disease
9.8.3. Huntington’s disease
9.8.4. Schizophrenia
9.8.5. Depression
9.8.6. Multiple Sclerosis
9.8.7. Spinal Muscular Atrophy (SMA)
9.9. Market Size (US$ Mn) Forecast By Application, 2017-2025
9.9.1. Alzheimer’s disease
9.9.2. Parkinson’s disease
9.9.3. Huntington’s disease
9.9.4. Schizophrenia
9.9.5. Depression
9.9.6. Multiple Sclerosis
9.9.7. Spinal Muscular Atrophy (SMA)
9.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
9.10.1. Research Institutes and Diagnostic Centers
9.10.2. Hospitals
9.11. Market Size (US$ Mn) Forecast By End User, 2017-2025
9.11.1. Research Institutes and Diagnostic Centers
9.11.2. Hospitals
9.12. Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Type
9.12.3. By Application
9.12.4. By End User
9.13. Key Representative Market Participants
9.14. Key Participants Market Presence (Intensity Map)
10. Europe Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Market forecast and analysis in Germany, France, Italy, Spain, U.K., Russia, and rest of Europe
10.1. Introduction
10.2. Key Regulations
10.3. Regional Market Dynamics
10.3.1. Drivers
10.3.2. Restraints
10.3.3. Trends
10.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
10.4.1. Germany
10.4.2. France
10.4.3. U.K.
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
10.5.1. Germany
10.5.2. France
10.5.3. U.K.
10.5.4. Spain
10.5.5. Italy
10.5.6. Russia
10.5.7. Rest of Europe
10.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
10.6.1. Genomics Biomarker
10.6.2. Proteomic Biomarker
10.6.3. Metabolomics Biomarker
10.6.4. Imaging biomarkers
10.6.5. Others
10.7. Market Size (US$ Mn) Forecast By Type, 2017–2025
10.7.1. Genomics Biomarker
10.7.2. Proteomic Biomarker
10.7.3. Metabolomics Biomarker
10.7.4. Imaging biomarkers
10.7.5. Others
10.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
10.8.1. Alzheimer’s disease
10.8.2. Parkinson’s disease
10.8.3. Huntington’s disease
10.8.4. Schizophrenia
10.8.5. Depression
10.8.6. Multiple Sclerosis
10.8.7. Spinal Muscular Atrophy (SMA)
10.9. Market Size (US$ Mn) Forecast By Application, 2017-2025
10.9.1. Alzheimer’s disease
10.9.2. Parkinson’s disease
10.9.3. Huntington’s disease
10.9.4. Schizophrenia
10.9.5. Depression
10.9.6. Multiple Sclerosis
10.9.7. Spinal Muscular Atrophy (SMA)
10.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
10.10.1. Research Institutes and Diagnostic Centers
10.10.2. Hospitals
10.11. Market Size (US$ Mn) Forecast By End User, 2017-2025
10.11.1. Research Institutes and Diagnostic Centers
10.11.2. Hospitals
10.12. Market Attractiveness Analysis
10.12.1. By Country
10.12.2. By Type
10.12.3. By Application
10.12.4. By End User
10.13. Key Representative Market Participants
10.14. Key Participants Market Presence (Intensity Map)
11. Asia Pacific Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Market forecast and analysis in China, India, Japan, ASEAN, Australia & New Zealand, and Rest of Asia Pacific
11.1. Introduction
11.2. Key Regulations
11.3. Regional Market Dynamics
11.3.1. Drivers
11.3.2. Restraints
11.3.3. Trends
11.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia and New Zealand
11.4.5. ASEAN
11.4.6. Rest of Asia Pacific
11.5. Market Size (US$ Mn) Forecast By Country, 2017–2025
11.5.1. China
11.5.2. India
11.5.3. Japan
11.5.4. Australia and New Zealand
11.5.5. ASEAN
11.5.6. Rest of Asia Pacific
11.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
11.6.1. Genomics Biomarker
11.6.2. Proteomic Biomarker
11.6.3. Metabolomics Biomarker
11.6.4. Imaging biomarkers
11.6.5. Others
11.7. Market Size (US$ Mn) Forecast By Type, 2017–2025
11.7.1. Genomics Biomarker
11.7.2. Proteomic Biomarker
11.7.3. Metabolomics Biomarker
11.7.4. Imaging biomarkers
11.7.5. Others
11.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
11.8.1. Alzheimer’s disease
11.8.2. Parkinson’s disease
11.8.3. Huntington’s disease
11.8.4. Schizophrenia
11.8.5. Depression
11.8.6. Multiple Sclerosis
11.8.7. Spinal Muscular Atrophy (SMA)
11.9. Market Size (US$ Mn) Forecast By Application, 2017-2025
11.9.1. Alzheimer’s disease
11.9.2. Parkinson’s disease
11.9.3. Huntington’s disease
11.9.4. Schizophrenia
11.9.5. Depression
11.9.6. Multiple Sclerosis
11.9.7. Spinal Muscular Atrophy (SMA)
11.10. Historical Market Size (US$ Mn) Analysis By End User, 2012-2016
11.10.1. Research Institutes and Diagnostic Centers
11.10.2. Hospitals
11.11. Market Size (US$ Mn) Forecast By End User, 2017-2025
11.11.1. Research Institutes and Diagnostic Centers
11.11.2. Hospitals
11.12. Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Type
11.12.3. By Application
11.12.4. By End User
11.13. Key Representative Market Participants
11.14. Key Participants Market Presence (Intensity Map)
12. MEA Neurological Biomarkers Market Analysis 2012–2016 and Forecast 2017–2025
Market forecast and analysis in GCC, South Africa, and Rest of MEA
12.1. Introduction
12.2. Key Regulations
12.3. Regional Market Dynamics
12.3.1. Drivers
12.3.2. Restraints
12.3.3. Trends
12.4. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of MEA
12.5. Market Size (US$ Mn) Forecast By Country, , 2017–2025
12.5.1. GCC Countries
12.5.2. South Africa
12.5.3. Rest of MEA
12.6. Historical Market Size (US$ Mn) Analysis By Type, 2012–2016
12.6.1. Genomics Biomarker
12.6.2. Proteomic Biomarker
12.6.3. Metabolomics Biomarker
12.6.4. Imaging biomarkers
12.6.5. Others
12.7. Market Size (US$ Mn) Forecast By Type, 2017–2025
12.7.1. Genomics Biomarker
12.7.2. Proteomic Biomarker
12.7.3. Metabolomics Biomarker
12.7.4. Imaging biomarkers
12.7.5. Others
12.8. Historical Market Size (US$ Mn) Analysis By Application, 2012-2016
12.8.1. Alzheimer’s disease

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report